Company Description
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market.
It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health.
It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression.
The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
| Country | Canada |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Dwight Gorham |
Contact Details
Address: 6420 Abrams Saint Laurent, A8 H4S 1Y2 Quebec, Canada | |
| Phone | 514-331-7440 |
| Website | intelgenx.com |
Stock Details
| Ticker Symbol | IGXT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001098880 |
| CUSIP Number | 45822R101 |
| ISIN Number | US45822R1014 |
| Employer ID | 87-0638336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dwight Gorham | Chief Executive Officer |
| André Godin C.A., CPA, CA, CPA | President and Chief Financial Officer |
| Tommy Kenny J.D., L.L.B., M.Sc. | Senior Vice President and General Counsel |
| Nadine Paiement M.Sc. | Vice-Chair of Scientific Advisory Board and Vice President of Research and Development - IntelGenx Corp |
| Karen Kalayajian CPA | Vice President of Finance and Administration |
| Stephen Kilmer | Investor Relations Officer |
| Ingrid Zerbe | Corporate Secretary |
| Zenoz Nina Pourhassan | Vice President of Quality Operations of Subsidiary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Apr 11, 2024 | QUALIF | Filing |
| Apr 5, 2024 | 1-A POS | Filing |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Feb 16, 2024 | QUALIF | Filing |